Howard Safran is an Oncology physician. ClinicalTrials.gov lists 33 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
164 Summit Ave
Fain 3
Providence, RI 029062853
Telephone
401-793-2920Registry record last updated 8 Jul 2007.
Clinical trials
- Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island
Sponsor: Rhode Island Hospital
- Biomarkers For Immune Checkpoint Inhibitors
Sponsor: Rhode Island Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20252 payments
- Daiichi Sankyo Inc.Program year20251 payment
- PFIZER INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
38%Serotonin-3 Receptor Antagonist14.3%Ondansetron Hcl100%Part D≥73 patientsProton pump inhibitor6.6%Pantoprazole Sodium54%Omeprazole46%Part D<11 patients+ 5 more classes in this area
Nervous system
32.7%Phenothiazine12.4%Prochlorperazine Maleate100%Part D≥65 patientsOpioid Agonist7.1%Oxycodone Hcl100%Part D≥20 patients+ 4 more classes in this area
Cancer & immunology
9.6%Kinase inhibitor9.6%Imatinib Mesylate83%Everolimus17%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1996–1997 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”